• In the media
  • COVID-19 Pandemic rattles already vulnerable...
Media - published on 24 Mar 2020

COVID-19 Pandemic rattles already vulnerable antibiotics market

Jessica Davis Plüss of SWI swissinfo.ch looks at how the COVID-19 pandemic is impacting the antibiotics market. The Access to Medicine Foundation's Antimicrobial Resistance Benchmark is cited for its insights into R&D in the field, and Executive Director Jayasree K. Iyer is quoted in the article.

This article looks into the long-standing issue of bacterial resistance to antibiotics as a result of antibiotic overuse and misuse, and the need for new medications as a response. This article delves into additional barriers that might affect the research, development, and access to new medications due to the COVID-19 pandemic. 

The article cites the Access to Medicine Foundation's 2020 Antimicrobial Resistance Benchmark findings that antibiotic R&D is becoming progressively more concentrated within a small number of companies. Jayasree Iyer is quoted as saying that “we are relying on very few companies to hold the world supply of antibiotics in check.”  



Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |